Company profile
Procyon Corporation
OTC: PCYN · Healthcare · Drug Manufacturers - Specialty & Generic
#709 of 1,418 Healthcare companies by revenue51st-percentile growth
EA Score
——FH —DQ 49GM —SS 55
v0.1 · 25/100 weight · pillars only
↑ growth stability, listing tenure · ↓ filing timeliness, Piotroski F
Methodology →Revenue TTM
$5.0M
Rev growth YoY (TTM)
+6.4%
Net income (FY)
-$341.1k
Employees
19
as of 2026-08-25
Market cap
$2.0M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$5.0M$5.0M2024
Net income-$341.1k-$341.1k2024
Operating income-$231.7k-$231.7k2024
Total assets$3.2M$3.2M2024
Liabilities$917.1k$917.1k2024
Equity$2.3M$2.3M2024
Revenue trend
FY2017 – FY2024 · USD
FY17
FY18
FY19
FY20
FY21
FY22
FY23
FY24
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Procyon Corporation’s revenue?
Procyon Corporation booked $5.0M in FY2024 revenue, growing 6.4% year over year — about the middle of the pack among Healthcare companies we track, at a -6.8% net margin.
Peers · Healthcare
Wellbeing Digital Sciences Inc.——Ensysce Biosciences, Inc.31DBanyan Corp.——InMed Pharmaceuticals Inc.45DPicard Medical, Inc.25DLucid Diagnostics Inc.35DNeighbors
Pinellas →Key facts
CEOJustice W. Anderson
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersClearwater, FL
ExchangeOTC: PCYN
Employees19
IPO date1996-12-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.